 PLANO, Texas, Dec. 04, 2020 GLOBE NEWSWIRE -- Reata Pharmaceuticals, Inc. Nasdaq: RETA Reata or the Company, a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 2,000,000 shares by the Company of its Class A common stock, at a price to the public of 140.85 per share, for gross proceeds of 281.7 million. Reata has granted the underwriters a 30-day option to purchase 300,000 additional shares of its Class A common stock, on the same terms and conditions as the shares offered in the public offering. 